Investigational Guillain-Barré Syndrome Treatment Granted FDA Fast Track Designation
September 24, 2019
Monoclonal antibody for autoimmune and neurodegenerative disorders.
SUBSCRIBE: Print / Digital / eNewsletter
Monoclonal antibody for autoimmune and neurodegenerative disorders.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
